Innovation is key to providing affordable healthcare for the world’s population
Read more
Join GE Healthcare and pharmaphorum for a tweetchat on neurological disorders
Read more
Mission to elevate patient care education standards
Read more
RSNA 2013 has crossed the finish line. This year’s RSNA theme of ‘The Power of Partnership’ underscores how crucial working with healthcare professionals will be for the continued success of radiology. The show is always an opportunity to learn about the latest technologies available and the trends the radiology industry is currently following.
Last in the series of videos from RSNA 2013, the focus is on developing technology to further improve patient experience.
One area where GE Healthcare pioneers in is breast cancer care. Through continued investment and development new technology continues to be introduced to meet the needs of patients and clinicians around the world.
GE Healthcare today announced the U.S. Food and Drug Administration (FDA) approval of Vizamyl™ (Flutemetamol F18 injection), a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.
Got any comments?
Please let us know what you think of this site.
